Financhill
Back

Inozyme Pharma Quote, Financials, Valuation and Earnings

Inozyme Pharma Price Quote

$3.02
-0.01 (1.34%)
(Updated: December 14, 2024 at 5:38 AM ET)

Inozyme Pharma Key Stats

Buy
74
Inozyme Pharma (INZY) is a Buy

Day range:
$2.81 - $3.10
52-week range:
$2.39 - $7.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.31%

Volume:
809.6K
Avg. volume:
703.3K
1-year change:
-24.63%
Market cap:
$191.4M
Revenue:
$0
EPS:
$-1.56

How Much Does Inozyme Pharma Make?

Data Unavailable

Is Inozyme Pharma Growing As A Company?

Data Unavailable

Inozyme Pharma Stock Price Performance

  • Did Inozyme Pharma Stock Go Up Last Month?
    Inozyme Pharma share price went down by -14.65% last month
  • Did INZY's Share Price Rise Over The Last Year?
    INZY share price fell by -24.63% over the past 1 year

What Is Inozyme Pharma 52-Week High & Low?

Inozyme Pharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Inozyme Pharma?

  • How Much Debt Does Inozyme Pharma Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Inozyme Pharma Have?
    Cash and short term investments quarterly total is $131.6M
  • What Is Inozyme Pharma’s Book Value Per Share?
    Book value per share is 1.29

Is Inozyme Pharma Cash Flow Positive?

  • What Is INZY Cash Flow From Operations?
    Cash flow from operations (TTM) is -$91.2M
  • What Is Inozyme Pharma’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $23.7M
  • What Is Inozyme Pharma’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $45.1M

Inozyme Pharma Return On Invested Capital

Data Unavailable

Inozyme Pharma Earnings Date & Stock Price

Inozyme Pharma Competitors

  • Who Are Inozyme Pharma's Competitors?
    Below is a list of companies who compete with Inozyme Pharma or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • CEL-SCI Corp (CVM)
    • IGC Pharma Inc (IGC)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Protalix BioTherapeutics Inc (PLX)

Inozyme Pharma Dividend Yield

Inozyme Pharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.83%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 19.56
Upside from Last Price: 545.4%

Major Shareholders

  • How many INZY shares are owned by institutional investors?
    68.8M INZY shares are owned by institutional investors
  • How many INZY shares are owned by insiders?
    716.3K INZY shares are owned by insiders